Compare Biogen Inc (BIIB) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Wayfair Inc — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while Wayfair Inc trades at $104.76 (market cap $14.14B). The key difference: Biogen Inc is far larger — about 2.1× Wayfair Inc's market cap. Which is the better fit depends on your goals.
| BIIB | W | |
|---|---|---|
Market Cap | $30.13B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $119.05 |
52-Week Low | $128.93 | $57.40 |
Enterprise Value | $37.20B | $16.47B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
